Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

By  

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 214-221

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-01 ,pp. : 3048-3056

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

By Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1399-1408

Springer Publishing Company

Access to resources Recommend Favorite

Diverse Models for the Prediction of Dual mTOR and PI3K Inhibitory Activities of Substituted 4-morpholinopyrrolopyrimidines

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 4, 2014-05 ,pp. : 454-473

Bentham Science Publishers

Access to resources Recommend Favorite